France Rejects Advice To Delay Second Dose Of Pfizer Vaccine
Health Minister Says Move Not Justified By The Evidence
Executive Summary
The French government has decided not to extend the recommended interval between the two doses of the Pfizer/BioNTech coronavirus vaccine.
You may also be interested in...
Coronavirus Notebook: EFPIA Attacks EU’s Vaccine Export Authorization Scheme, EMA Starts Rolling Review Of REGN-COV2 Antibody Combo
Médecins Sans Frontières has urged Johnson & Johnson to prioritize vaccine supplies to COVAX, the EMA has clarified the dosing interval for Pfizer/BioNTech’s Comirnaty, and the UK has ordered more vaccine from Valneva.
French HTA Body Backs Routine Six-Week Interval In COVID-19 Vaccine Dosing
France's health technology assessment body says that delaying by six weeks the second dose of the two mRNA vaccines approved for use against COVID-19 would allow at least 700,000 more people to receive their jab in the first month.
EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods
Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.